Nov 5, 2025 | H&P News, M&A
The CDMO landscape is evolving rapidly, with certain segments — such as biologics, cell and gene therapies and advanced aseptic manufacturing — experiencing strong growth, while more traditional small-molecule and generics-focused areas face increasing margin pressure...
